Semi-Annual Report — FY2026 H1
What Carna Biosciences,Inc. reported for the period from 2026-01-01 to 2026-12-31. Filed by カルナバイオサイエンス株式会社
Filed 2026-08-07View the original on EDINET
How much it says
63Detailed
What moved here
23named for the first time
Its own wording
37terms
Which filing this is
34/ 34newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period (1 January 2026 to 30 June 2026), the drug discovery business continued clinical trials but recorded no revenue, while revenue from the drug discovery support business increased and operating income improved. The company also advanced financing through bond issuance and conversions and the exercise of stock acquisition rights, bringing cash and cash equivalents to ¥1,100 million at the period-end.
Komori's summary of this document, not the document's own words.63Detailed
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 34 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
79
Very detailed
94
Very detailed
62
Detailed
0
Almost nothing
15
Almost nothing
68
Detailed
71
Detailed
100
Very detailed
60
Detailed
79
Very detailed
50
Typical
R&D spend9億円Money spent making new things.
Cash left over9億円Cash from the business, less what went into equipment.
Spent on equipment5百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.